| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA907: Deucravacitinib for treating moderate to severe plaque psoriasis |
|
Medicine details |
|
| Medicine name | deucravacitinib (Sotyktu®) |
| Formulation | oral medicine |
| Reference number | 4071 |
| Indication | Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Skin |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 05/06/2023 |
| NICE guidance | TA907: Deucravacitinib for treating moderate to severe plaque psoriasis |